[vc_row full_width=”stretch_row” css=”.vc_custom_1531732107238{background-color: #fcc118 !important;}”][vc_column]

[/vc_column][/vc_row][vc_row css=”.vc_custom_1531730959461{border-bottom-width: 1px !important;background-color: #f9fafb !important;border-bottom-color: #eef3f7 !important;border-bottom-style: solid !important;}”][vc_column css=”.vc_custom_1531891416301{margin-bottom: 0px !important;}”][bsfp-cryptocurrency style=”widget-6″ align=”auto” columns=”2″ scheme=”light” coins=”top-x-coins” coins-count=”8″ coins-selected=”” currency=”USD” title=”Cryptocurrencies” show_title=”0″ icon=”” heading_color=”” heading_style=”default” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ css=”.vc_custom_1531730265600{margin-bottom: 0px !important;}” custom-css-class=”” custom-id=””][/vc_column][/vc_row]

Rite Aid Corp. (RAD) Q1 2024 adj. loss narrows; revenue down 6%


Drugstore chain Rite Aid Corporation (NYSE: RAD) announced first-quarter results, reporting lower revenues and a narrower adjusted loss.

First-quarter loss, excluding special items, improved to $0.73 per share from a loss of $0.86 per share in the same period of last year. On a reported basis, the net loss attributable to common stockholders was $306.7 million or $5.56 per share, compared to a loss of $110.2 million or $2.03 per share in the prior-year quarter.

Total revenues decreased modestly to $5.65 billion in the first quarter from $6.01 billion in the corresponding period of 2023. Retail comparable same-store prescriptions moved up 4.7%, while front-end same-store sales, excluding cigarettes and tobacco products, decreased by 3.8%.

“Our first quarter results were driven by strong script growth, solid pharmacy margins, and early progress with our turnaround program, which offset underperformance on front-end sales in the Retail Pharmacy Segment and a higher-than-expected medical loss ratio at Elixir Insurance,” said interim chief executive officer Elizabeth Burr.

Prior Performance

Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More